Athersys Past Earnings Performance
Past criteria checks 0/6
Athersys's earnings have been declining at an average annual rate of -12.5%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 44% per year.
Key information
-12.5%
Earnings growth rate
3.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -44.0% |
| Return on equity | n/a |
| Net Margin | -46,883.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Athersys makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -38 | 10 | 0 |
| 30 Jun 23 | 0 | -47 | 10 | 0 |
| 31 Mar 23 | 2 | -58 | 13 | 0 |
| 31 Dec 22 | 5 | -73 | 15 | 0 |
| 30 Sep 22 | 6 | -81 | 19 | 0 |
| 30 Jun 22 | 11 | -84 | 19 | -35 |
| 31 Mar 22 | 8 | -83 | 18 | 0 |
| 31 Dec 21 | 6 | -87 | 20 | 0 |
| 30 Sep 21 | 6 | -87 | 19 | 0 |
| 30 Jun 21 | 1 | -94 | 19 | 35 |
| 31 Mar 21 | 1 | -90 | 19 | 0 |
| 31 Dec 20 | 1 | -79 | 16 | 0 |
| 30 Sep 20 | 0 | -66 | 14 | 0 |
| 30 Jun 20 | 0 | -56 | 13 | 0 |
| 31 Mar 20 | 4 | -47 | 12 | 0 |
| 31 Dec 19 | 6 | -45 | 11 | 0 |
| 30 Sep 19 | 7 | -46 | 12 | 0 |
| 30 Jun 19 | 10 | -44 | 11 | 0 |
| 31 Mar 19 | 25 | -27 | 11 | 0 |
| 31 Dec 18 | 24 | -24 | 10 | 0 |
| 30 Sep 18 | 24 | -26 | 10 | 0 |
| 30 Jun 18 | 22 | -24 | 9 | 0 |
| 31 Mar 18 | 3 | -37 | 9 | 0 |
| 31 Dec 17 | 4 | -32 | 8 | 0 |
| 30 Sep 17 | 4 | -26 | 8 | 0 |
| 30 Jun 17 | 3 | -25 | 8 | 0 |
| 31 Mar 17 | 3 | -26 | 8 | 0 |
| 31 Dec 16 | 17 | -15 | 8 | 0 |
| 30 Sep 16 | 27 | -5 | 8 | 0 |
| 30 Jun 16 | 27 | -5 | 8 | 0 |
| 31 Mar 16 | 27 | 1 | 8 | 0 |
| 31 Dec 15 | 12 | -16 | 8 | 0 |
| 30 Sep 15 | 2 | -27 | 7 | 0 |
| 30 Jun 15 | 1 | -25 | 7 | 0 |
| 31 Mar 15 | 2 | -23 | 7 | 0 |
| 31 Dec 14 | 2 | -22 | 7 | 0 |
| 30 Sep 14 | 2 | -25 | 7 | 0 |
| 30 Jun 14 | 3 | -26 | 7 | 0 |
| 31 Mar 14 | 3 | -33 | 6 | 0 |
| 31 Dec 13 | 2 | -31 | 6 | 0 |
| 30 Sep 13 | 4 | -24 | 6 | 4 |
| 30 Jun 13 | 4 | -22 | 6 | 8 |
| 31 Mar 13 | 6 | -20 | 6 | 12 |
Quality Earnings: 4LSA is currently unprofitable.
Growing Profit Margin: 4LSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4LSA is unprofitable, and losses have increased over the past 5 years at a rate of 12.5% per year.
Accelerating Growth: Unable to compare 4LSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4LSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 4LSA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.